home / stock / apvo / apvo news

APVO News and Press, Aptevo Therapeutics Inc. From 02/09/22

Stock Information
Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com
Menu
APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...
APVO - Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on de...
APVO - Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022 SEATTLE, WA / ACCESSWIRE / January 21, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ...

APVO - Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"

LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / December 15, 2021 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced publication of an article in the December 15, 2021, issue of the peer-reviewed journal, Nature Communications , on the m...

APVO - LCID, EDIT and BLUE among pre market gainers

Arena Pharmaceuticals (NASDAQ:ARNA) +90% on acquisition by Pfizer. Foghorn Therapeutics (NASDAQ:FHTX) +38% after collaborating with Lilly in oncology medicines. BELLUS Health (NASDAQ:BLU) +36% on positive BLU-5937 data in mid-stage chronic cough study. Petros Pha...
APVO - Krystal Biotech, Petros Pharmaceuticals leads healthcare gainers; Fennec Pharmaceuticals, Allied Healthcare Products among major losers

Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...

APVO - ESPR, LOV and BFRA among mid-day movers

Gainers: Biofrontera (NASDAQ:BFRI) +154%. Longeveron (NASDAQ:LGVN) +79%. Ocuphire Pharma (NASDAQ:OCUP) +36%. Society Pass (NASDAQ:SOPA) +24%. Biofrontera (NASDAQ:BFRA) +23%. Better Therapeutics (NASDAQ:BTTX) +20%. Applied UV (NASDAQ:AUVI) +19%. Standard Lithium (NYSE:SLI) +19%. Blue Star Food...

APVO - Biofrontera, Longeveron leads healthcare gainers; Vallon Pharmaceuticals, Pasithea Therapeutics among major losers

Gainers: Biofrontera (NASDAQ:BFRI) +109%, Longeveron (NASDAQ:LGVN) +87%, Ocuphire Pharma (NASDAQ:OCUP) +41%, Better Therapeutics (NASDAQ:BTTX) +24%, Reviva Pharmaceuticals (NASDAQ:RVPH) +12%. Losers: Vallon Pharmaceuticals (NASDAQ:VLON) -34%, Pasithea Therap...
APVO - XL, CLMT and AYTU among pre market gainers

Pasithea Therapeutics (NASDAQ:KTTA) +172% adds Esketamine nasal spray to its clinic offerings in the U.K. Petros Pharmaceuticals (NASDAQ:PTPI) +99%. iSpecimen ISPC +99% is set to extend rally after contract win for COVID-19 research Qualigen Therapeutics (NASDAQ:QLGN) +72%. Aad...

APVO - Aptevo gains nearly double after APVO436 + chemotherapy resulted in complete remission in AML

Aptevo Therapeutics (NASDAQ:APVO) soars 99.4% premarket after announcing a clinical update for its Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia (AML). A high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO43...

APVO - Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform techno...
Previous 10 Next 10